Warning letter
kubapharm.com: warning letter of Mar 30, 2022
FDA warning letter 622051 · Center for Drug Evaluation and Research | CDER
Key facts
| Reference number | 622051 |
|---|---|
| Company | kubapharm.com |
| Subject | Unlawful Sale of Schedule II Stimulants to Consumers over the Internet |
| Issue date | Mar 30, 2022 |
| Posted date | Apr 12, 2022 |
| Issuing office | Center for Drug Evaluation and Research | CDER |
| Product type | Drugs |
| Country | 3 |
| Letter on fda.gov | fda.gov |
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: